SPOTLIGHT -
EP. 1: Treatment of Bone Metastases in Prostate Cancer
EP. 2: Defining Symptomatic in Prostate Cancer
EP. 3: Factors Impacting Treatment Approach in Advanced Prostate Cancer
EP. 4: Combining Radium-223 With Other Therapies in Prostate Cancer
EP. 5: Local and Systemic Therapeutic Options in Low-Volume Prostate Cancer
EP. 6: Candidacy for Chemotherapy in Oligometastatic Prostate Cancer
EP. 7: Potential Predictive Markers in Prostate Cancer
EP. 8: Safety of Low-Dose Steroids with Abiraterone in Prostate Cancer
EP. 9: Therapeutic Options in Metastatic CRPC
EP. 10: CRPC: Patient Selection in AR-Directed Therapies
EP. 11: Abiraterone Plus Prednisone in CRPC: Factors to Consider
EP. 12: First-Line Options in Muscle-Invasive Bladder Cancer
EP. 13: Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer
EP. 14: Check Point Inhibition in Muscle-Invasive Bladder Cancer
EP. 15: Approaches in High-Risk Non-Muscle Invasive Bladder Cancer
EP. 16: Measuring Response in Non-Muscle Invasive Bladder Cancer
EP. 17: The Role of Biomarkers in Bladder Cancer
EP. 18: A Look Ahead in Genitourinary Cancers
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
